Stockscreener 앱 받기
2.85
4.68%
-0.14
시간 외 거래:
2.91
0.06
+2.11%
Corvus Pharmaceuticals Inc 주식(CRVS)의 최신 뉴스
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2024 Earnings Call Transcript - MSN
Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials - Seeking Alpha
Corvus Pharmaceuticals Stock: Now At Cruising Altitude (NASDAQ:CRVS) - Seeking Alpha
Corvus Pharmaceuticals at H.C. Wainwright Conference: Socolitinib’s Promising Trials By Investing.com - Investing.com Canada
Institutions along with retail investors who hold considerable shares inCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) come under pressure; lose 24% of holdings value - simplywall.st
Corvus Pharmaceuticals’ Earnings Call: Progress Amid Challenges - MSN
Corvus Pharma Stock Dips On Bigger-Than-Feared Q4 Loss, But Retail’s Faith Grows Stronger - Asianet Newsable
Insider Buyers At Corvus Pharmaceuticals Sitting On US$1.3m Profit - Yahoo Finance
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $15 From $14, Maintains Outperform Rating - MarketScreener
Corvus Pharmaceuticals Inc (CRVS) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Corvus Pharmaceuticals Reports 2024 Financial Results and Clinical Progress - TipRanks
Earnings call transcript: Corvus Pharmaceuticals Q4 2024 sees wider loss By Investing.com - Investing.com Canada
Corvus: Q4 Earnings Snapshot - Greenwich Time
Earnings call transcript: Corvus Pharmaceuticals Q4 2024 sees wider loss - Investing.com India
Corvus Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
CORVUS PHARMACEUTICALS Earnings Results: $CRVS Reports Quarterly Earnings - Nasdaq
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
CORVUS PHARMACEUTICALS Earnings Preview: Recent $CRVS Insider Trading, Hedge Fund Activity, and More - Nasdaq
Corvus Pharmaceuticals Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Brokerages Set Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) PT at $12.38 - Armenian Reporter
Corvus Pharma Reports Positive Data From Phase 1/1b Study Of Soquelitinib In T Cell Lymphoma - Nasdaq
Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma - The Manila Times
New Cancer Drug Achieves 39% Response Rate in T Cell Lymphoma Patients - Stock Titan
Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - The Manila Times
Corvus Pharma Reveals Autoimmune Pipeline Strategy at Major HC Wainwright Conference - Stock Titan
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - The Manila Times
Corvus Pharmaceuticals to Host Conference Call for Q4 and Full Year 2024 Financial Results on March 25, 2025 - Nasdaq
Corvus Pharmaceuticals Reveals Q4 Earnings Date: Complete Financial Picture Coming March 25 - StockTitan
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) - The Manila Times
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for ... - The Bakersfield Californian
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with - EIN News
Corvus Pharmaceuticals: Small Market, Many Competitors, Low Cash Balance (NASDAQ:CRVS) - Seeking Alpha
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of “Buy” from Analysts - Armenian Reporter
Insiders Enjoy US$1.7m Return After Buying Corvus Pharmaceuticals Stock - Simply Wall St
Adicet Bio (NASDAQ:ACET) versus Corvus Pharmaceuticals (NASDAQ:CRVS) Head to Head Analysis - Defense World
When (CRVS) Moves Investors should Listen - Stock Traders Daily
Head to Head Survey: Adagene (NASDAQ:ADAG) and Corvus Pharmaceuticals (NASDAQ:CRVS) - Defense World
Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - The Manila Times
Exclusive Healthcare Insights: Corvus Pharma Takes Center Stage at Major Oppenheimer Conference - StockTitan
JPMorgan Chase & Co. Buys 40,404 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - Defense World
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives $12.38 Average Target Price from Analysts - Defense World
Analysts Set Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) PT at $12.38 - MarketBeat
Cantor Fitzgerald Comments on CRVS FY2025 Earnings - Defense World
Equities Analysts Offer Predictions for CRVS FY2025 Earnings - MarketBeat
CRVS’s Stock Market Adventure: -8.04% YTD Growth Amidst Volatility - The InvestChronicle
Corvus Pharmaceuticals (NASDAQ: CRVS) Announces Positive Interim Data from Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisOn January 13, 2025, Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company, released encouraging int - Defense World
10.70%
자본화:
|
볼륨(24시간):